Results 71 to 80 of about 195,829 (332)

Cholesterol in mRNA‐Lipid Nanoparticles can be Replaced with the Synthetic Mycobacterial Monomycoloyl Glycerol Analogue MMG‐1

Advanced Functional Materials, EarlyView.
This study demonstrates that cholesterol in messenger RNA‐lipid nanoparticles (mRNA‐LNPs) can be completely replaced with an immunopotentiating lipid, i.e., a synthetic analogue of the C‐type lectin receptor agonist monomycoloyl glycerol (MMG‐1), without compromising physicochemical properties, in vivo transfection efficiency, and immunogenicity of the
Abhijeet G. Lokras, Saahil S. Baghel, Rune F. Jensen, Aneesh Thakur, Henrik Franzyk, Oskar Thofte, Marco Herrera‐Barrera, Madeleine Landry, Melike Ongun, Ahmad Tami, Marlene P. Thanthrige, Eva Callens, Corinne Beinat, Thomas Rades, Søren R. Paludan, Kristian Riesbeck, Ida Rosenkrands, Dennis Christensen, Gabriel K. Pedersen, Camilla Foged   +19 more
wiley   +1 more source

Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression

Drug Design, Development and Therapy, 2016
Dawn Bruijnzeel, Rajiv Tandon Department of Psychiatry, University of Florida College of Medicine, Gainesville, FL, USA Abstract: Antipsychotic agents, utilized for the treatment of a range of psychiatric disorders, differ substantially in terms of ...
Bruijnzeel D, Tandon R
doaj  

Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole

Neuropsychopharmacology Reports, 2021
Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify®).
Tetsuro Kikuchi, Kenji Maeda, Mikio Suzuki, Tsuyoshi Hirose, Takashi Futamura, Robert D. McQuade   +5 more
doaj   +1 more source

The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs [PDF]

, 2013
G protein coupled receptors (GPCRs) are the most historically successful therapeutic targets. Despite this success there are many important aspects of GPCR pharmacology and function that have yet to be exploited to their full therapeutic potential.
Hudson, Brian D., Milligan, Graeme, Ulven, Trond   +2 more
core   +1 more source

Evaluation of partial ?-adrenoceptor agonist activity [PDF]

British Journal of Clinical Pharmacology, 1997
A partial β‐adrenoceptor (β‐AR) agonist will exhibit opposite agonist and antagonist activity depending on the prevailing degree of adrenergic tone or the presence of a β‐AR agonist with higher intrinsic activity. In vivo partial β‐AR agonist activity will be evident at rest with low endogenous adrenergic tone, as for example with chronotropicity (β1 ...
Brian J. Lipworth, Alison Grove
openaire   +3 more sources

3D‐Printed Scaffolds Promote Enhanced Spinal Organoid Formation for Use in Spinal Cord Injury

Advanced Healthcare Materials, EarlyView.
3D‐printed organoid scaffolds with microscale channels are developed to enhance spinal cord injury recovery by guiding region‐specific spinal neural progenitor cells. These scaffolds promote axonal growth, cell maturation, and neuronal network formation.
Guebum Han, Nicolas S. Lavoie, Nandadevi Patil, Olivia G. Korenfeld, Hyunjun Kim, Manuel Esguerra, Daeha Joung, Michael C. McAlpine, Ann M. Parr   +8 more
wiley   +1 more source

Dissolving Microneedle for Maintaining the Integrity of HPV Virus‐Like Particles Enabling Durable Sterile Protection Across Various Mucosal Tissues

Advanced Healthcare Materials, EarlyView.
A novel dissolving microneedle platform preserves HPV virus‐like particle (VLP) immunogenicity by maintaining structural integrity, crucial for eliciting potent immune responses. Buccal administration induces robust immune response, high neutralizing antibody titers, and durable sterile protection across oral and vaginal mucosal sites.
Hyemi Kim, Inhyuk Hwang, Juhee Seo, Chaiwon Kim, In‐Jeong Choi, Miran Kang, Min‐Seok Rha, Youngjae Hong, Jooyoung Kim, Seung‐Ki Baek, Jung‐Hwan Park, Hyung‐Ju Cho, Kihyuck Kwak   +12 more
wiley   +1 more source

Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. [PDF]

, 2019
Mood disorders are highly prevalent and are the leading cause of disability worldwide. The neurobiological mechanisms underlying depression remain poorly understood, although theories regarding dysfunction within various neurotransmitter systems have ...
Dulawa, Stephanie C, Janowsky, David S
core  

The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice. [PDF]

, 2015
RATIONALE Using the drinking-in-the-dark (DID) model, we compared the effects of a novel mu-opioid receptor antagonist, GSK1521498, with naltrexone, a licensed treatment of alcohol dependence, on ethanol consumption in mice.
C Giuliano, C Giuliano, David N. Stephens, David R. Wille, DM Ignar, DN Stephens, DW Oslin, EA Rabiner, Edward T. Bullmore, EE Codd, F Kiefer, GH Jones, H Wit de, H Ziauddeen, HM Pettinati, JR Volpicelli, JS Rhodes, Kay Maltby, LA Berner, LA Parker, LD Middaugh, LS Hwa, Manolo Mugnaini, NK Kamdar, P Monti, PJ Nathan, PJ Nathan, Pradeep Nathan, S Loeber, Sam R. Miller, Sandra Sanchez-Roige, Tamzin L. Ripley, TJ Phillips, TL Ripley   +33 more
core   +1 more source

Nanocarrier‐Based Targeting of Pattern Recognition Receptors as an Innovative Strategy for Enhancing Sepsis Therapy

Advanced Healthcare Materials, EarlyView.
This review highlights recent progress in nanocarriers targeting pattern recognition receptors (PRRs), including Toll‐like and NOD‐like receptors, for enhancing the treatment of bacterial sepsis and related complications. These nanomedicines deliver antibiotics and anti‐inflammatory agents while modulating immune responses.
Eman A. Ismail, Vincent O. Nyandoro, Calvin A. Omolo, Thirumala Govender   +3 more
wiley   +1 more source